Lanvis is a Prescription medicine medicine

Main Indication

Acute myeloblastic leukaemia. Less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. Although superior results are generally obtained with busulphan (Myleran) in the treatment of chronic granulocytic leukaemia. LANVIS may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. A degree of cross resistance exists between LANVIS (thioguanine) and Puri-Nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. Unlike mercaptopurine the detoxification of LANVIS is not dependent on xanthine oxidase, hence therapy with LANVIS is not affected by the xanthine oxidase inhibitor, allopurinol (Zyloprim). Recent evidence suggests that LANVIS is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. Not effective for the treatment of chronic lymphocytic leukaemia or solid tumours. The aim of therapy is to achieve normal appearance of the bone marrow and peripheral blood. It is recognised, however, that in treating acute leukaemia, one may not always be able to achieve complete remissions and must be satisfied with partial improvement.

Therapeutic Area


Lanvis is available in these strengths:

  • Lanvis 40mg Tablets 25s Pack
  • Lanvis 40mg Tablets Bottle